I do want to discuss manufacturing - I think it is where CYP sinks or swims. I do think the Nature Medicine article is the best basis for that discussion.
You asked a good question previously "how do you account for the rollout" or something similar. I wrote a response to that post but didn't post it in the end as it needed more work. There is in my opinion an absolute wealth of information in that Nature Medicine article but it doesn't come out easily. The supplementary information has volumes and lists of "ingredients" for each of the media. With a bit of reverse engineering of the numbers quite a lot of insight can be gained in my opinion. And important questions for CYP are, in my opinion, how much inventory does CYP currently have on hand, and can CYP actually offer potential partners more convincing proof of scalability. I think that is almost a completely separate issue to producing the trivial amounts of cells needed even for an OA trial.
I do mean to respond to your other post.
CYP Price at posting:
69.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)